About CSL Biotherapies' Australian Operations

CSL Biotherapies is Australia’s chosen national plasma fractionator and, under contract to Australia’s National Blood Authority, manufactures a complete range of life saving plasma-derived therapies for the treatment of the Australian community. The range of plasma-derived therapies we manufacture for Australia is the largest manufactured in a single facility globally. It is also the only range in which every product is manufactured using processes that include at least two dedicated and complementary pathogen reduction steps. We are also the chosen national plasma fractionator of New Zealand, Hong Kong, Malaysia, Singapore and Taiwan. 

In Australia, CSL Biotherapies also manufactures and in-licenses, markets and distributes vaccines with particular focus on vaccines for the prevention and treatment of serious disease. We operate one of the world’s largest influenza vaccine manufacturing facilities and supply seasonal influenza vaccines to Australia and global markets. 

Working closely with public health authorities and the Australian Department of Health & Ageing we have used our influenza vaccine technology to develop and license a safe and effective pandemic influenza vaccine providing biosecurity to Australia’s population in the event of an influenza pandemic such as the 2009 swine flu.We are Australia’s first line of defence against pandemic influenza. 

In addition, we in-license a range of pharmaceutical products from our partner companies to ensure a comprehensive range of products are available to meet the needs of all Australians.

We manufacture a Snake Venom Detection Kit and antivenoms to protect Australia's community from envenomation by our most venomous creatures.

CSL Biotherapies also manufactures a range of immunohaematology products (diagnostic reagents) that are supplied to Australian laboratories to enhance the safety of blood transfusions for patients in Australia.

Our heritage underpins our strong commitment to research and development, reliability, safety and quality. This philosophy has resulted in the development of many life-saving products and allowed us to play a key role in the collaborative work that has delivered the world’s first vaccine against cervical cancer.

CSL’s Australian operations are also a signatory to the Australian Packaging Covenant (APC). As part of our commitment to the goals and principles of the APC, an action plan has been developed with actions that will integrate the principles sustainable packaging and product stewardship into packaging design process. Access to additional information can be found on the APC website - www.packagingcovenant.org.au.

Download the latest APC action plan (2011-2015) for CSL Biotherapies